Tiziana Life Sciences (AIM:TILS) excellent progress and exciting times ahead.
Following the release of its interim results for the six months ended 30 June 2015, we are taking a look at progress from this interesting AIM biotech
This biotechnology company, founded in 2013, is focusing on the development of unique therapeutics to target cancer and autoimmune diseases. They have made a number of substantial progressions this year, giving them a positive outlook in targeting currently unmet medical needs. One of the company’s research priorities is to develop a drug that can target advanced, or ‘metastatic’, breast cancer. This late-stage of the disease is responsible for a huge number of cancer deaths, highlighting a clear gap in the market for developments that could improve survival rates in patients. Current treatment options for metastatic cancers include hormone therapy and…